Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. (2nd January 2019)

• Record Type: Journal Article
• Authors: Zai, Clement C.; Tiwari, Arun K.; Chowdhury, Nabilah I.; Yilmaz, Zeynep; de Luca, Vincenzo; Müller, Daniel J.; Potkin, Steven G.; Lieberman, Jeffrey A.; Meltzer, Herbert Y.; Voineskos, Aristotle N.; Remington, Gary; Kennedy, James L.
• Is Part Of: World journal of biological psychiatry. Volume 20:Number 1(2019)
• Page Start: 91
• Page End: 95
• Publication Date: 2019-01-02
• Subjects: Tardive dyskinesia -- schizophrenia -- pharmacogenetics -- neuregulin 1 (NRG1) -- receptor tyrosine-protein kinase erbB-4 (ERBB4); Biological psychiatry -- Periodicals; Biological Psychiatry -- Periodicals; 616.89
• DOI: 10.1080/15622975.2017.1301681
• Languages: English
• ISSNs: 1562-2975

Abstract

Abstract: Objectives: Tardive dyskinesia (TD) is a movement disorder that may develop as a side effect of antipsychotic medication. The aetiology underlying TD is unclear, but a number of mechanisms have been proposed. Methods: We investigated single-nucleotide polymorphisms (SNPs) in the genes coding for neuregulin-1 and erbB-4 receptor in our sample of 153 European schizophrenia patients for possible association with TD. Results: We found the ERBB4 rs839523 CC genotype to be associated with risk for TD occurrence and increased severity as measured by the Abnormal Involuntary Movement Scale (AIMS) ( P = .003). Conclusions: This study supports a role for the neuregulin signalling pathway in TD, although independent replications are warranted.